- REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
- REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
- REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
- REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
- REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
- REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
More ▼
Key statistics
On Friday, Regenxbio Inc (RGNX:NSQ) closed at 23.13, 23.76% above the 52 week low of 18.69 set on May 24, 2022.
52-week range
Markit short selling activity
Open | 23.00 |
---|---|
High | 23.29 |
Low | 22.75 |
Bid | 18.19 |
Offer | 30.77 |
Previous close | 23.00 |
Average volume | 310.41k |
---|---|
Shares outstanding | 43.29m |
Free float | 39.98m |
P/E (TTM) | 24.96 |
Market cap | 1.00bn USD |
EPS (TTM) | 0.9266 USD |
Data delayed at least 15 minutes, as of Jan 27 2023 21:00 GMT.
More ▼